Abstracts tagged "registry"

Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 1000 • ACR Convergence 2024
Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Hafsah Nabi², Dorte Vendelbo Jensen³, Jens Pedersen⁴, Oliver Hendricks⁵, Anne Gitte Loft⁶, Ada Colic⁷, Kamilla Danebod³, Salome Kristensen⁸, Heidi Munk⁹, Niels Lomborg¹⁰, Natalia Manilo¹¹, Stavros Chrysidis¹², Søren Just¹³, Asta Linauskas¹⁴, Pil Højgaard¹⁵, Pia Høger Thygesen¹⁶, Malene Kildemand¹⁷, Rene Drage Oestgaard¹⁸, Merete Hetland¹⁹ and Bente Glintborg²⁰, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ⁵Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, ⁷Department of Rheumatology, Zealand University Hospital, Koege, Denmark, ⁸Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, ¹¹Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹²Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ¹³Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ¹⁴Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ¹⁵Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, ¹⁶Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁷Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, ¹⁸Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ²⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
Abstract Number: 1952 • ACR Convergence 2024
Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Michael Fisher¹, Mimi Kim², Joan Merrill³, Safoah Agyemang¹ and Joy Buie¹, ¹Lupus Foundation of America, Washington, DC, ²Albert Einstein College of Medicine, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many treatments under study for SLE, a crisis in recruiting sufficient numbers of qualified patients for clinical trials has emerged. Willingness to consider…
Abstract Number: 0136 • ACR Convergence 2024
Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
Federico Zazzetti¹, Urbano Sbarigia², William Giovanini³, Claire Blacketer⁴, Michel van Speybroeck⁵, Teresa A. Simon⁶, Guo Li³, Chetan S. Karyekar⁴, Reyhan Sonmez⁷, Manuel Ugarte-Gil⁸, RV, Gamboa-Cardenas⁹, Victor Pimentel-Quiroz¹⁰, Guillermo Pons-Estel¹¹, Bernardo Pons-Estel¹², Rosana Quintana¹³, Veronica Saurit¹⁴, ODIRLEI MONTICIELO¹⁵, Katiuzka Zuñiga Corrales¹⁶, Jorge Esquivel-Valerio¹⁷, Martin Rebella¹⁸, Cecilia Pisoni¹⁹, Francinne Machado Ribeiro²⁰, Carlos Núñez-Álvarez²¹, Kaleb Michaud²², Patricia Katz²³, Rangi Kandane-Rathnayake²⁴, Eric Morand²⁵, Worawit Louthrenoo²⁶, Yi-Hsing Chen²⁷, Jiacai Cho²⁸, Laniyati Hamijoyo²⁹, Shue Fen Luo³⁰, Yeong-Jian Jan Wu³⁰, Sandra Navarra³¹, Sargunan Sockalingam³², Masayoshi Harigai³³, Zhuoli Zhang³⁴, BMDB Basnayake³⁵, Madelynn Chan³⁶, Tsutomu Takeuchi³⁷, Sang-Cheol Bae³⁸, Fiona Goldblatt³⁹, Sean O'Neill⁴⁰, Kristine (Pek Ling) Ng⁴¹, Yih Jia Poh⁴², Nicola Tugnet⁴³, Sunil Kumar⁴⁴, Michael Tee⁴⁵, Yoshiya Tanaka⁴⁶ and Chak Sing. Lau⁴⁷, Alberta Hoi⁴⁸, Mandana Nikpour⁴⁹, Mark Sapsford⁵⁰, Íñigo Rúa-Figueroa⁵⁰, José María Pego-Reigosa⁵¹, María Galindo-Izquierdo⁵², Jaime Calvo-Alén⁵³, Antonio Fernández-Nebro⁵⁴, Raúl Menor Almagro⁵⁵ and Frederic Lavie⁵⁶, ¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Physicians Research Center, LLC, Toms River, NJ, ⁷EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ⁹Universidad Científica del Sur, Lima, Lima, Peru, ¹⁰Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ¹³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁴hospital privado universitario de cordoba, Córdoba, Argentina, ¹⁵HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁶Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ¹⁷Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ¹⁸Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ¹⁹CEMIC, Buenos Aires, Argentina, ²⁰Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²²University of Nebraska Medical Center, Omaha, NE, ²³University of California San Francisco, San Francisco, CA, ²⁴Monash University, Clayton, Victoria, Australia, ²⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²⁶Chiang Mai University, Chang Wat Chiang Mai, Thailand, ²⁷Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ²⁸National University Hospital, Kent Ridge, Singapore, ²⁹University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, ³⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), ³¹University of Santo Tomas, Manila, Philippines, ³²University of Malaya Medical Centre, Kuala Lumpur, Malaysia, ³³Tokyo Women's Medical University, Tokyo, Japan, ³⁴Peking University First Hospital, Beijing, China, ³⁵Teaching Hospital, Kandy, Sri Lanka, ³⁶Tan Tock Seng Hospital, Singapore, Singapore, ³⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³⁹Flinders Medical Centre, Adelaide, Australia, ⁴⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ⁴¹Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, ⁴²SingHealth, Singapore, Singapore, ⁴³Auckland District Health Board, Auckland, New Zealand, ⁴⁴Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, ⁴⁵University of the Philippines, Manila, Philippines, ⁴⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴⁷University of Hong Kong, Pok Fu Lam, Hong Kong, ⁴⁸Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ⁴⁹The University of Sydney, Melbourne, Victoria, Australia, ⁵⁰Middlemore Hospital, Auckland, New Zealand, ⁵⁰Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁶Galicia Health Service (SERGAS), Vigo, Spain, ⁵²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵³Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁵⁴Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ⁵⁵Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁵⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
Abstract Number: 1028 • ACR Convergence 2024
Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Nancy Pan², Catherine Bingham³, Sheetal Vora⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Erik Friedrichsen⁷, Michelle Batthish⁸, Jon Burnham⁹, Danielle Fair¹⁰, Suhas Ganguli¹¹, Mileka Gilbert¹², Beth Gottlieb¹³, Olha Halyabar¹⁴, Melissa Hazen¹⁵, Tzielan Lee¹⁶, Daniel Lovell¹⁷, Melissa Mannion¹⁸, Edward Oberle¹⁹, Linda Ray²⁰, Michael Shishov²¹, Mary Toth²² and Esi Morgan²³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Penn State Children’s Hospital, Hershey, ⁴Atrium Health Levine Children's Hospital, Charlotte, NC, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁷Seattle Children's Hospital, Seattle, ⁸McMaster Children's Hospital, Hamilton, ON, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹¹Hackensack University Medical Center, Hackensack, ¹²Medical University of South Carolina, Charleston, SC, ¹³Cohen Children's Medical Center, Lake Success, NY, ¹⁴Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Stanford University School of Medicine, Palo Alto, CA, ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Nationwide Children's Hospital, Columbus, OH, ²⁰University of Mississippi Medical Center, Jackson, MS, ²¹Phoenix Children's Hospital, Phoenix, AZ, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care…
Abstract Number: 2054 • ACR Convergence 2024
Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Paula García Escudero¹, Marta López I Gómez², Berta Magallanes López³, Diego Dios Santos⁴, Francisco Javier Toyos Sáenz de Miera⁵, Alicia García Dorta⁶, José Ángel Hernández Beriain⁷, Íñigo Rúa-Figueroa⁸, cristiana sieiro santos⁹, Elvira Díez Álvarez¹⁰, Marta Ibáñez Martínez¹¹, Beatriz Frade-Sosa¹², Judit Font Urgelles¹³, Meritxell Sallés Lizarzaburu¹⁴, Elena Riera Alonso¹⁵, Ernesto Trallero Araguás¹⁶, Eugenia Enríquez Merayo¹⁷, Maria Rodriguez-Laguna¹⁸, irene monjo¹⁹, Carolina Merino²⁰, Paloma Vela-Casasempere²¹, Ignacio Vázquez Gómez²², Jose Alberto Miranda Filloy²³, Rafael Benito Melero-Gonzalez²⁴, Clara Garcia Belando²⁵, Giuliano Boselli²⁶, Alina Lucica Boteanu²⁷, Dolly Viviana Fiallo Suárez²⁸, Cristina Corrales Selaya²⁹, ALBERTO MARIANO RUIZ ROMAN³⁰ and Jaime Calvo-Alén³¹, ¹Hospital Universitario Araba, Vitoria, ²Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ⁴C. H. U. A Coruña, C. H. U. A Coruña, ⁵H. U. Virgen Macarena, H. U. Virgen Macarena, ⁶Rheumatologist, La Laguna, Spain, ⁷Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ⁸Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁰Complejo Asistencial Universitario de León, León, Spain, ¹¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clinic de Barcelona, Barcelona, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ¹⁵Mutua de Terrasa, Barcelona, ¹⁶Hospital Vall D'Hebron, Barcelona, Spain, ¹⁷Hospital 12 de Octubre, Madrid, ¹⁸Resident in Rheumatology, Madrid, Spain, ¹⁹University Hospital La Paz, Madrid, Spain, ²⁰Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²¹Hospital General Universitario Alicante, Alicante, Spain, ²²H. U. Dr. Peset, Valencia, ²³C. H. U. Lucus Augusti, Lugo, Spain, ²⁴CHU Ourense, O Carballino, Spain, ²⁵H. C. U. Virgen de la Arrixaca, Murcia, ²⁶hospital miguel servet, zaragoza, Aragon, Spain, ²⁷H.U. Ramón y Cajal, Madrid, Spain, ²⁸H. U. de Gran Canaria. Dr. Negrin, H. U. de Gran Canaria, ²⁹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ³⁰Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, ³¹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is an autoinflammatory disorder caused by a mutation in the UBA1 gene, which leads to a heterogeneous clinical presentation and progressive bone…
Abstract Number: 0282 • ACR Convergence 2024
Electronic Health Record-Based Calcium Pyrophosphate Deposition Disease Registry: A Feasibility Study
Nils Bürgisser¹, Denis Mongin², Samia Mehouachi², Delphine Sophie Courvoisier³ and Kim Lauper⁴, ¹Division of Rheumatology and internal medicine, Geneva University Hospital, Switzerland, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Despite its prevalence, calcium pyrophosphate deposition disease (CPPD) remains insufficiently studied. Leveraging electronic health record (EHR) data, a rich source of patient information, could…
Abstract Number: 1114 • ACR Convergence 2024
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
paula pérez garcía¹, Miriam Retuerto Guerrero², yanira chuquimia mendoza³, Jesús Loarce⁴, Belén Atienza-Mateo⁵, Carolina Merino⁶, marina pavia pascual⁷, cristiana sieiro santos⁸, Clara Moriano⁹ and elvira Diez álvarez¹⁰, ¹Complejo Asistencial Universitario de León, león, Spain, ²Complejo Asistencial Universitario de León, Leon, Spain, ³Complejo asistencial univeritario de león, león, Spain, ⁴Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Hospital General Universitario Gregorio Marañon, madrid, Spain, ⁸Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 0345 • ACR Convergence 2024
Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
Chester Oddis¹, Jan Feifel², Dana Ascherman³, Diane Carol Koontz⁴, Caroline Foch², Luisa Henkel⁵, Jeffrey M. Muir⁶, Deborah Denis⁷ and Rohit Aggarwal⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²the healthcare business of Merck KGaA, Darmstadt, Germany, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany, Weiterstadt, Germany, ⁶Cytel, Inc., Toronto, Canada, ⁷EMD Serono, Rockland, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Glucocorticoids (GC) in high doses remain the first-line treatment for dermatomyositis (DM). One or more immunosuppressive agents are given concomitantly as steroid-sparing agents to…
Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Masataka Kuwana¹, Kenichi Masui², Atsushi Kawakami³, Takafumi Suda⁴, Shinji Sato⁵, Yasushi Kawaguchi⁶, Takeshi Johkoh⁷, Tomoaki Hoshino⁸, Naoki Shimada⁹, Yasuhiro Kondoh¹⁰, Yoshinori Tanino¹¹, Tohru Takeuchi¹², Yoshiyuki Abe¹³, Naoki Kimura¹⁴, Yasushi Inoue¹⁵, Keisuke Tomii¹⁶, Toru Arai¹⁷, Kunihiro Yamaoka¹⁸, Kaneshige Sasaki¹⁹, Taio Naniwa²⁰, Ran Nakashima²¹, Kenjiro Shima²², Osamu Nishiyama²³, Yuko Waseda²⁴, Hiroshi Mukae²⁵, Hirofumi Chiba²⁶, Keigo Ikeda²⁷, Kazuya Ichikado²⁸, Yohei Kirino², Koichi Amano²⁹, Takashi Nawata³⁰, Tomoo Kishaba³¹, Daisuke Asatori³², Daisuke Kobayashi²² and Takahisa Gono³³, ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ²Yokohama City University School of Medicine, Yokohama, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁵Tokai University School of Medicine, Isehara, Japan, ⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁷Kansai Rosai Hospital, Amagasaki, Japan, ⁸Kurume University School of Medicine, Kurume, Japan, ⁹International University of Health and Welfare, Ohtawara, Japan, ¹⁰Tosei General Hospital, Seto, Japan, ¹¹Fukushima Medical University School of Medicine, Fukushima, Japan, ¹²Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ¹⁶Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁷NHO Kinki Chuo Chest Medical Center, Sakai, Japan, ¹⁸Kitasato University School of Medicine, Sagamihara, Japan, ¹⁹Kainan Hospital, Yatomi, Japan, ²⁰Nagoya City University, Nagoya, Japan, ²¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²²Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²³Kindai University Faculty of Medicine, Osakasayama, Japan, ²⁴University of Fukui, Eiheiji, Japan, ²⁵Nagasaki University Hospital, Nagasaki, Japan, ²⁶Sapporo Medical University, Sapporo, Japan, ²⁷Juntendo University Urayasu Hospital, Urayasu, Japan, ²⁸Saiseikai Kumamoto Hospital, Kumamoto, Japan, ²⁹Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, ³⁰Yamaguchi University Graduate School of Medicine, Ube, Japan, ³¹Okinawa Chubu Hospital, Uruma, Japan, ³²Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ³³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
Abstract Number: 2208 • ACR Convergence 2024
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Aparna Swaminathan¹, Jeremy Weber², Jamie Todd³, Scott Palmer³, Megan Neely³, Peide Li⁴ and Ann Chauffe⁵, and on behalf of the ILD-PRO Registry investigators, ¹Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT
Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
Abstract Number: 0378 • ACR Convergence 2024
Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Michelle Batthish⁷, Jon Burnham⁸, Danielle Fair⁹, Suhas Ganguli¹⁰, Mileka Gilbert¹¹, Beth Gottlieb¹², Tzielan Lee¹³, Daniel Lovell¹⁴, Melissa Mannion¹⁵, Edward Oberle¹⁶, Nancy Pan¹⁷, Linda Ray¹⁸, Michael Shishov¹⁹, Mary Toth²⁰ and Esi Morgan²¹, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Hackensack University Medical Center, Hackensack, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵University of Alabama at Birmingham, Birmingham, AL, ¹⁶Nationwide Children's Hospital, Columbus, OH, ¹⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ¹⁸University of Mississippi Medical Center, Jackson, MS, ¹⁹Phoenix Children's Hospital, Phoenix, AZ, ²⁰Nemours Foundation, Orlando, FL, ²¹Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
Abstract Number: 1226 • ACR Convergence 2024
The Problem of Pain in Systemic Lupus Erythematosus: A Comprehensive Analysis of Pain Distribution Using the CHOIR Body Map and PROMIS Measures
Tiffany Jiang¹, Sean Mackey², Beth Darnall², Julia Simard³ and Titilola Falasinnu⁴, ¹Yale School of Medicine, New Haven, CT, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE), characterized by an autoimmune attack of healthy tissues, presents a complex collection of symptoms affecting multiple organ systems. Among these,…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].